Progress in the clinical cure of the population of inactive hepatitis B surface antigen carriers
10.3760/cma.j.cn501113-20231116-00201
- VernacularTitle:非活动性HBsAg携带状态人群临床治愈进展
- Author:
Zhishuo MO
1
;
Zhiliang GAO
Author Information
1. 中山大学附属第三医院感染科，广州 510630
- Keywords:
Hepatitis B surface antigen;
Inactive hepatitis B surface antigen carriers;
Disease progression;
Pegylated interferon alpha;
Clinical cure;
HBsAg clearance
- From:
Chinese Journal of Hepatology
2023;31(12):1336-1339
- CountryChina
- Language:Chinese
-
Abstract:
The population of inactive HBsAg carriers (IHCs) is enormous, and it is often overlooked because of the insidious progression and mild severity of the disease. With the continuous enrichment and consolidation of research evidence, the population of IHC has obtained a high clinical cure rate through a treatment strategy based on pegylated interferon α and a stronger treatment intention. This article reviews the definition and treatment recommendations of IHCs in current domestic and international guidelines, as well as the disease progression and clinical cure research progress, so as to provide a reference and basis for scientific management and rational therapeutics.
